Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PMA TO CREATE NEW TOP LOBBYING POSITION TO COORDINATE FEDERAL AND STATE ACTIVITIES; McKINSEY ANALYSIS TO BE REVIEWED BY COMMITTEE HEADED BY de VINK

Executive Summary

The Pharmaceutical Manufacturers Association is recruiting a new senior lobbyist to coordinate federal and state activities as an outgrowth of the recent McKinsey analysis of functions and structure. The Washington lobbying effort has been headed by VP Michael Reed, reporting to President Gerald Mossinghoff. The state government activities have been directed by VP Woody Allen, reporting to Senior VP Bruce Brennan.

You may also be interested in...



PhRMA Strategic Planning Effort Will Have McKinsey Touch

PhRMA is working with the McKinsey consulting firm on its strategic planning effort for 2004

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel